Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)

Amylyx Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at -$665000.0 for Q4 2024.

• In Q4 2024, Gross Profit fell 101.0% year-over-year to -$665000.0; the TTM figure through Sep 2025 stood at -$665000.0 (down 100.44% YoY), while the FY2024 annual figure was $81.4 million, down 77.09% from the prior year.
• Gross Profit was -$665000.0 for Q4 2024 at Amylyx Pharmaceuticals, down from $416000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $102.8 million in Q2 2023 to a low of -$665000.0 in Q4 2024.
• Historically, Gross Profit has averaged $44.9 million across 3 years, with a median of $42.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Gross Profit soared 25893.33% in 2023, then tumbled 101.0% in 2024.
• A 3-year view of Gross Profit shows it stood at $18.9 million in 2022, then jumped by 253.11% to $66.6 million in 2023, then sank by 101.0% to -$665000.0 in 2024.
• The last three Gross Profit figures came in at -$665000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024), per Business Quant data.